Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel

Author： Briasoulis Evangelos   Karavasilis Vasilis   Tzamakou Eleftheria   Rammou Dimitra   Soulti Kali   Piperidou Christina   Pavlidis Nicholas  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.53, Iss.5, 2004-05, pp. : 452-457

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase II study of pegylated liposomal doxorubicin (Caelyx&unknown;) as induction chemotherapy for patients with squamous cell cancer of the head and neck

By Harrington K.J.   Lewanski C.   Northcote A.D.   Whittaker J.   Peters A.M.   Vile R.G.   Stewart J.S.W.  

European Journal of Cancer, Vol. 37, Iss. 16, 2001-11 ,pp. : 2015-2022

Elsevier

Access to resources Recommend Favorite

Phase II trial of pegylated liposomal doxorubicin (Caelyx™) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer

By Ulrich-Pur Herbert   Kornek Gabriela   Haider Karin   Kwasny Werner   Payrits Thomas   Dworan Nina   Vormittag Laurenz   Depisch Dieter   Lang Fritz   Scheithauer Werner  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 208-213

Informa Healthcare

Access to resources Recommend Favorite

Safety and Activity of the Combination of Pegylated Liposomal Doxorubicin and Weekly Docetaxel in Advanced Breast Cancer

By Morabito Alessandro  

Breast Cancer Research and Treatment, Vol. 86, Iss. 3, 2004-08 ,pp. : 249-258

Springer Publishing Company

Access to resources Recommend Favorite

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL(R)/CAELYX(R)) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma - a study by the EORTC Soft Tissue and Bone Sarcoma Group

By Judson I.   Radford J.A.   Harris M.   Blay J.-Y.   van Hoesel Q.   le Cesne A.   van Oosterom A.T.   Clemons M.J.   Kamby C.   Hermans C.   Whittaker J.   Donato di Paola E.   Verweij J.   Nielsen S.  

European Journal of Cancer, Vol. 37, Iss. 7, 2001-05 ,pp. : 870-877

Elsevier

Access to resources Recommend Favorite

Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?

By Mamidi Rao   Weng Steve   Stellar Susan   Wang Charles   Yu Ning   Huang Tony   Tonelli Alfred   Kelley Michael   Angiuoli Anthony   Fung Man-Cheong  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 6, 2010-11 ,pp. : 1173-1184

Springer Publishing Company

Access to resources Recommend Favorite